Exelixis (EXEL)

Executive Summary

Exelixis is a commercial-stage oncology biopharmaceutical company with a market cap of ~$11.3B, driven by its flagship product cabozantinib (Cabometyx), approved for renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. The company continues to invest in its pipeline, including the next-generation tyrosine kinase inhibitor zanzalintinib (XL092), which is being evaluated across multiple solid tumors in Phase 2/3 trials, and early-stage assets like XB371. With growing revenues from cabozantinib, a strong balance sheet over $2.3B in cash, and a royalty stream from partnered drugs, Exelixis is well-positioned for sustained growth. Key near-term value drivers include data readouts from ongoing combination trials and potential label expansions, particularly in frontline settings where cabozantinib-based combinations could address significant unmet needs.

Upcoming Catalysts (preview)

• H2 2026Phase 3 data readout for cabozantinib + atezolizumab in first-line renal cell carcinoma (CONTACT-01)70% success
• Q3 2026FDA decision on cabozantinib + nivolumab for advanced hepatocellular carcinoma (CheckMate 9DW)80% success
• Q2 2026Initial Phase 1/2 clinical data for zanzalintinib in solid tumors at ASCO 202660% success